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Over the next 10–20 years, a pessimistic prognosis considers pandemic scenario for type 2 diabetes mellitus,
neurodegenerative disorders and some types of cancer followed by the economic disaster of healthcare systems in
a global scale. Well-recognised deficits of currently provided medical services result from the delayed ‘disease care’.
Herewith EPMA releases the long-term strategies for the effective promotion of predictive, preventive and personalised
medicine (PPPM) considered as the medicine of the future. Under the EPMA-umbrella, an international forum of
currently 45 countries is actively contributing to the development and implementation of the innovative PPPM
concepts. EPMA is open for collaboration with other leading European and global professional networks relevant
for the effective promotion of PPPM in sciences and practical implementation.
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Over the next 10–20 years, a pessimistic prognosis con-
siders pandemic scenario for an increasing number of
chronic diseases, such as type 2 diabetes mellitus, neurode-
generative disorders, some types of cardiovascular diseases
and cancer followed by the economic disaster of healthcare
systems in a global scale. Well-recognised deficits of
current healthcare is the delayed ‘disease care’ with all
negative consequences such as the low efficacy of medical
services, decreased quality of the patient life, frequent hos-
pitalisation and increasing economical and societal burden.
‘We have the knowledge for disaster reduction, what
we need is the action’ [1].PPPM—medicine of the future and evidence-based
platform to advance healthcare
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article, unless otherwise stated.the person, from reactive to preventive medicine and from
disease to wellness. Predictive, preventive and personalised
medicine (PPPM) is the new integrative concept in health-
care sector that enables to predict individual predispos-
ition before onset of the disease, to provide targeted
preventive measures and create personalised treatment
algorithms tailored to the person. Integrative approach by
PPPM is considered as the medicine of the future. The
cost-effective management of health promotion and
disease care implements the innovation by PPPM in
modernisation of medical services. Being at the fore-
front of the global efforts, the European Association for
Predictive, Preventive and Personalised Medicine
(EPMA, http://www.epmanet.eu/) promotes the integra-
tive concept of PPPM amongst healthcare stakeholders,
governmental institutions, educators, funding bodies,
patient organisations and in the public domain [2]. Under
the EPMA-umbrella, an international forum of currently
45 countries is actively contributing to the development
and implementation of the innovative PPPM concepts (see
Figure 1) worldwide. The main structures altogether
create a consolidated scientific, technological and educa-
tional platform and elaborate the long-term strategies of
the association, namely:Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 International EPMA platform: worldwide 45 countries actively contribute to the creation and implementation of innovative
PPPM concepts in medical sciences, technologies and healthcare. The group of the National Representatives (National EPMA BOARDs) is the
key element in the structure of the association which consolidates and coordinates the EPMA-related activities at the national level closely working with
all PPPM-related national institutions, units and groups such as Federations of Patients, Universities, research units, state and private hospitals, insurance,
industrial groups, policy-makers, etc. More information—please see the EPMA website www.epmanet.eu.
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– Industrial Advisory Board (Figure 3)
– Specialised professional sections (see below)
– Group of the section-responsible Associate Editors
(see below)
– Young professionals section, EPMA-YPS (Figure 4)
– EPMA/Springer book series ‘Advances in PPPM’
Long-term strategies of the European Association
for Predictive, Preventive and Personalised
Medicine
Prioritised medical fields listed and shortly described
below have been approved as being of strategic interests
of the association. The study was approved by the
EPMA BOARD of Directors, Group of Associate editors
responsible for individual sections, EPMA Institutional
members and EPMA Industrial Advisory Board. Conse-
quent realisation will be organised by the EPMA using
following instruments:
➢ multilateral professional and international collaborations,
➢ excellent research activities,
➢ high-quality publications (The EPMA Journal, EPMA
Book-Series and other instruments),➢ scientific projects responding to the calls of the
‘Horizon 2020’ (and other appropriate national and
international programmes), international meetings
(EPMA Summits/World Congresses and other
appropriate forums) [3],
➢ implementation of the evidence-based research
achievements for an effective advancing of healthcare
by innovative medical services (creation and qualifi-
cation of PPPM centres of excellence),
➢ PPPM-related education for both professionals and
general population,
➢ effective career promotion of young professionals
creating a highly qualified professional elite for the
realisation of PPPM objectives via new generations of
experts in the EU and global scale.
Specialised professional sections
1. Healthcare and Medical Services (responsible
editor: Vincenzo Costigliola, Belgium)
In healthcare, realisation of optimistic versus
pessimistic prognosis depends on current
innovations in diagnostic and cost-effective treatment
approaches widely adopted in clinical practice. How
Figure 2 EPMA institutional members create a nucleus of the
expert working groups in the association consolidating
professionals for effective networking in PPPM, promoting
high-quality topic related research and contributing to creation
of guidelines in European healthcare. EPMA institutional
members are the long-term partners participating in the thematic
international projects and dedicated European programmes such as
‘Horizon 2020’.
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medicine and adopt innovative approaches in
healthcare systems, whilst promoting predictive
diagnostics, targeted preventive measures and
individualised patient treatment on a global scale?
EPMA has created a scientific forum for professionals
to discuss this topic. The main objectives of these
efforts are to mark stakeholders in the field, to
consolidate professional groups and to elaborate
expert recommendations of how to optimise these
approaches for the patient [4,5].
2. Cardiovascular Disease (responsible editors:
Hiroyasu Iso, Japan, and Hans-Peter Brunner-La
Rocca, The Netherlands)
The field of cardiovascular disease (CVD) is one of
the major targets for PPPM. There is a large body
of evidence concerning cardiovascular risk factors
and preventive strategies at both population and
individual levels but also chronic disease stages that
are not adequately addressed because they do not
follow the PPPM principles. This section focuses on
the broad aspects of basic, clinical and
epidemiological studies. The promotion of PPPM in
the treatment of CVD is a global health issue, since
the health burden from CVD is currently the most
severe in most developed countries and is rapidly
increasing in most developing countries. It is
therefore of the utmost importance to exchange on
a global-level scientific insights, knowledge and skills
for risk prediction of cardiovascular disease, and to
share and adopt various experience for its prevention
and the development of personalised treatment
approaches [6,7].
3. Cancer (responsible editors: Dominic Desiderio,
USA, and Byong Chul Yoo, South Korea)
Cancer research shows that more data are needed
on the molecular basis (genes, transcriptomes,
proteomes, PTMs) of each cancer; molecular
changes during development of a cancer; and
treatment. A new paradigm in medicine—predictive,
preventive, and personalised medicine—clarifies
mechanisms, yields an accurate diagnosis and leads
to effective treatment. We have a unique molecular
environment; cancer develops differently in each
person; and we respond individually to drugs. One
Figure 3 EPMA Industrial Advisory Board (IAB) is the main
structure in the association bridging research and
implementation activities in PPPM. IAB provides professional
advices considering innovative concepts, practical needs and related
strategies. Members of the IAB are the long-term partners invited by
the association in consensus with thoroughly elaborated criteria for
a partnership which the mission is to effectively promote the field
of PPPM.
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accelerates cancer research and treatment [8,9].
4. Neurological, Neuropsychiatric and Neurodegenerative
Diseases (NNND) (responsible editors: Friedemann
Paul, Germany & Silvia Mandel, Israel)
Neuropsychological/neuropsychiatric ailments and
progressive neurodegeneration are common features
of the majority of socially and economically
devastating disorders and diseases with
multifactorial physical and cognitive disability.Figure 4 The specialised ‘Young Professional Section’ aims at
the promotion of education and career of young professionals
in the field of PPPM; for more information—please
see www.epmanet.eu.NNND have pathologies of a multifactorial nature
involving interplay of epigenetic and environmental
risk factors. Insights into molecular
pathomechanisms will facilitate the creation of the
most effective targeted protective strategies and
individualised treatment before pathologies manifest.
Multifunctional (multi-drug) therapies should be
tailored to individual multi-aetiological aspects of the
disorders, in order to advance healthcare of patient
cohorts. Particular emphasis should be placed on
primary prevention by the identification of predisposed
individuals early on in life, followed by treatments
tailored to the person, which need regulations
supported by innovative reimbursement programmes.
This strategy creates a robust platform for the
cost-effective medicine of the future [10-13].
5. Diabetes (responsible editors: Mahmood S.
Mozaffari, USA, and Babak Baban, USA)
The worldwide increase in the incidence and
prevalence of diabetes mellitus (DM) continues to
exert alarming burden on healthcare systems. The
consequent cost impact poses a major challenge
for both developed and developing countries/
economies. These prevailing conditions provide
the rationale for the concept of PPPM: the
prediction of persons at risk should help devise
strategies for treatments tailored to the individual
and to prevent target organ complications of DM,
thereby, reducing morbidity and mortality and
associated costs. EPMA emphasises the need to
address the integrative approach for diabetes care
and innovative science focused on the patient
[14].
6. Rare Diseases (RDs) (responsible editor: Meral
Özgüc, Turkey)
RD is defined as being a rare one, if it affects less
than 5 persons per 10,000 individuals. Although
each individual RD is rare, altogether they are
5,000–8,000 distinct RDs affecting many millions of
people worldwide. Currently, it is estimated that in
Europe alone, there are at least 30 million of RD
patients. Almost 80% of RDs have a genetic origin
with symptoms appearing in prenatal and early
postnatal periods. Currently, there are no
appropriate treatment approaches for most of the
RDs. The only reasonable approach seems to be a
development of methods for early diagnosis of RDs
that might lead to the creation of the optimal care
management saving lives and improving life quality
within the patient cohort. The improvement in RDs
healthcare is initiated by legislations in EU and the
USA to create an integrative medical approach for
RDs. How the emerging paradigm of PPPM may
improve healthcare in RDs? Due to the molecular
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that the multimodal approach (*omics,
pharmacogenetics, medical imaging, etc.) with high
multidisciplinarity of professionals should be
instrumental for the ‘personalisation’ to diagnose
individual RDs, to create effective preventive
measures and to develop targeted therapies—the
integrative medical approach by PPPM [15].
7. Traditional Complementary and Alternative
Medicine (responsible editors: Paolo Roberti di
Sarsina, Italy, and Wei Wang, China)
This section provides a platform for innovative
strategies in science and healthcare demonstrating
how traditional, complementary and alternative
medicine (TCAM) can enrich the paradigm of
predictive, preventive and personalised medicine.
Evidence-based TCAM scientific approaches should
demonstrate high levels of person-centred and
participatory medicine, functional links between
TCAM, predictive diagnostics, targeted prevention
and individualised treatments in healthcare education
and clinical practice. Topics should explore tailoring
care by investigating and treating the person as a
physical, psychological and spiritual unicum living in
dynamic interaction with nature and society.
Individualise the therapeutic process by renewing
the caregiver-person relationship with trust,
compassion and respect for personal choices.
Explore innovative research methods to evaluate
TCAM and other salutogenetic interventions as a
form of preventive medicine empowering
communities and individuals [16-18].
8. Pain Management (responsible editor: Rostyslav
Bubnov, Ukraine)
This section demonstrates the highest levels of
multidisciplinarity and benefits from excellent
competencies of all medical fields (including
neuroscience, psychology, imaging, sport medicine
and TCAM) and complex technological
instruments (including hybrid technologies). The
main focus is a deep diagnostics followed by
creating individualised treatment algorithms. The
research and review articles are invited, dealing
with pain-relevant issues within integrated vision
of PPPM. This includes topics relevant animal
models, translation research, novel physiological,
safe and personalised therapies developed for
minimally interventional pain management and
physiotherapy, such as dry needling, neuromodu-
lation, etc. Regenerative therapy, guided by
advanced imaging techniques, using 3D modelling,
prospects for development of rapid prototyping,
robotics, smart prosthetics, etc. are the desirable
focuses of innovation of the pain management.This section aims to encourage publications
relevant to practitioners and researchers in a variety
of medical fields, covers topics of musculoskeletal
disorders, rheumatologic, orthopaedic, neurologic
conditions involving acute and chronic pain,
peripheral nervous systems, rehabilitation and
military medicine. Further, research to predictive,
preventive and prognostic pain management
relevant biomarkers is considered by the section.
Articles dedicated to self-assessment as well as focused
on creation of smart questionnaires are welcome.
Prevention of a wide spectrum of collateral diseases
(NDD, metabolic syndrome, cancer) linked to the
pain management may be considered in the context
of the improved healthcare policy and economic
benefits of the societies [19].
9. Dentistry (responsible editor: Mahmood S.
Mozaffari, USA)
Oral/dental health contributes to the overall health and
well-being of everybody. A growing body of evidence
demonstrates that the manifested dental and oral
pathologies are linked to the increased risk of various
diseases including heart and lung disease, vascular
pathologies, stroke, diabetes mellitus, neurological
disorders, pre-term birth and even some types of
cancer, amongst others. Further, certain oral symptoms
are considered as the early indicator of a spectrum of
the mental disorders such as anorexia, bulimia, anxiety
and depression. On the other hand, dental diseases
themselves may be caused by acute and chronic
systemic disorders such as diabetes mellitus.
Whilst an association between oral/dental diseases
and systemic disorders is well established, the
cause-and-effect relationships in these conditions
are poorly understood, an investigation of which is
a prerequisite for predictive, preventive and
personalised dental medicine [20-22].
10.Transplantation (responsible editor: Hele Everaus,
Estonia)
Cell and organ transplantation has obtained extremely
important role in the treatment of several severe and
fatal diseases. Long waiting lists of patients worldwide
reflect major problems and current deficits in
transplantation medicine. Prediction and
personalisation in transplantation are essential that
require an identification of individual pre- and
post-transplantation biomarker panels allowing
better donor/recipient matching and assessment of
individual risks. Improved donor-recipient matching,
person-centred immunosuppressive regimens,
individual risk assessment for chronic allograft damage
and prediction of graft accommodation—altogether
may lead to substantially increased allograft survival
and decreased patient morbidity, therefore, advancing
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vivid research on stem cells creates new perspectives
in the area. An integration of basic sciences at
molecular level, technological advances and clinical
sciences is crucial to progress the area and satisfy
the unmet patient needs in the field. Further, medical
ethics, smart political regulations and economy have
remarkable impacts on advances in transplantation
and regenerative medicine, in general.
11.Clinical Nutrition, Environment and Health
Psychology (responsible editors: Guglielmo M.
Trovato, Italy, and Niva Shapira, Israel)
The growing body of knowledge on nutrition requires
the dissemination of well-elaborated information
within the scientific and public domains. This
section focuses on integrative medical approaches
for individualised nutrition by means of predictive,
preventive and personalised medicine. It aims to
create professional opinions and to enhance and
develop knowledge and skills taking into account
evidence-based scientific achievements in the
fields of epidemiology, healthy lifestyle, optimised
nutrition, food science/technology/culture, medical
ethics and cost-effective healthcare and environmental
and affordable strategies. We welcome innovative
approaches for nutrition in health and disease, which
can then be used to build up expert recommendations
and standardisation. Our goal is to produce an
evidence-based consensus for sustainable guidelines in
predictive medicine together with targeted prevention
in healthy individuals, persons at-risk and stratified
patient groups with manifest diseases and provide
advice to stratified patient groups, institutions, food
producers and marketing experts [23,24], also using
the assessment and intervention tools of clinical
nutrition and health psychology. Health and disease
main determinants are genetic, environmental and
behavioural, and each component is merged and
interacts with the others. Environment is a still
neglected topic in PPPM; nonetheless, geography,
climate, anthropic modification, urban, rural and
occupational, agriculture and fishing are all subsets
that should be considered, along with societal issues
and political and economical implication, for increasing
the possibility of successful outcomes in health
promotion. A greater attention is warranted within
the comprehensive objectives of research, also in
other field, with a perspective of predictive, preventive
and personalised medicine.
12.Body Culture and Sports Medicine (BCSP)
(responsible editors: Rostyslav Bubnov, Ukraine, and
Halina Podbielska, Poland)
This section aims to understand how basic and
clinical research can be applied to personalised andpreventive strategies as set out by the framework of
EPMA. BCSP covers a wide spectrum of topics,
ranging from but not limited to exercise, healthy
lifestyle, personalised sleep algorithms, homoeopathy,
physical therapy, rehabilitation and others.
Disease-modifying effects that manifest in disease
states, such as hypertension, hypercholesterolemia,
obesity, neurodegenerative disorders, etc., are in
the focus of this section. High-quality research
based on measurable effects (including clinical criteria,
imaging and molecular biomarkers) that are associated
with modifiable factors (nutrients, physical activity,
lifestyle, etc.) is promoted by this section, with a
particular focus on research for individually tailored
interventions [25-27].
13.Translational Medicine (responsible editors: Anna
Chioti, Luxembourg, and Mikhail Paltsev, Russia)
This section aims to bridge excellent achievements
in basic and applicative sciences with an effective
implementation of innovative approaches in PPPM
to advanced healthcare services to the patients.
With the increasingly complex relationship between
basic research and clinical application, there is a
pressing need to bridge the translational gap from
bench to clinic using integrative methods. Topics
should explore advances in pathophysiology, disease
modelling, biomarker discovery and validation, novel
diagnostics (including companion diagnostics) in
personalised medicine which should help translate
knowledge from studies at the bench side to care at
the bed side. Clinical trials and public health studies
generating data allow to develop new research
hypotheses with a potential to unlock new
mechanisms. New approaches in drug development,
including data management, bioinformatics and
systems biomedicine, allow to address the whole
continuum of translation research in genomic
medicine: from gene discovery to health application,
to evidence-based guideline, to health practice and
finally to health impact [28,29].
14.Information and Communication Technologies
(ICT) (responsible editors: Heinz U. Lemke,
Germany, and Michael Legg, Australia)
PPPM proposes innovative strategies towards an
ICT-based holistic presentation of the individual
patient and corresponding medical processes/
procedures. These strategies imply a redesign of
healthcare activities within a given domain of medical
discourse, such as cardiovascular, neurological,
diabetic or oncologic disorders. ICT systems support
provided by a medical information and model
management system-like architecture, which
includes a number of carefully selected diagnostic
and therapeutic core functionalities, is the prerequisite
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of a specific patient based on appropriate mathematical
modelling methods, such as probabilistic relational
models and process models as well as advanced
ICT-enabling tools, the practice of medicine will be
substantially transformed towards model-based
medical evidence, providing transparency of clinical
situations, processes and decisions for patient and
physician. ICT approaches may result in profound
and cost-effective modernisation of healthcare. The
beneficiaries of these transforming methods and
technologies will include patients, healthcare providers
and society at large [30,31].
15.Innovative Technologies (IT) (responsible editors:
Kurt Krapfenbauer, Austria, and Xianquan Zhan,
China)
This section promotes any technological innovation
which may lead to advanced healthcare services such
as non-invasive, early and predictive diagnostics,
targeted prevention and treatments tailored to the
person. IT can be used for identification, as well as
characterisation and validation of clinically relevant
biomarkers. For example, medical imaging, sub-cellular
imaging, *omics (genomics, transciptomics,
proteomics, metabolomics, etc.) and hybrid
technologies developed can be used to identify
potential biomarker patterns at several molecular
levels. Based on IT such as highly sensitive
molecular chip technologies, the biomarker
research has faced many significant challenges.
The use of biomarkers and novel technologies to
investigate clinically relevant information allows
proper patient stratification into therapeutic
groups and improved therapy outcomes. If
detected well in time, smart molecular alterations
can optimise therapy outcome in specific
therapeutic groups. Integrating this information
allows selection of personalised targeted treatment
regimes, saving unnecessary drug toxicity and
decreasing morbidity [32-34].
16.Pharmacogenetics (responsible editors: Godfrey
Grech, Malta, and Romano Danesi, Italy)
Currently, the use of genetic information to treat
patients is still in its early stages, with some clear
successes mostly in the oncology and infectious
disease therapeutic areas. Some successful examples
include the targeting of tailored pharmaceuticals
developed for the treatment of patients with a
particular disease subtype or according to a specific
genetic makeup pertaining to the drug’s mode of
action. In other examples, genetic information is
being used to help determine the effective and safe
dose of specific pharmaceuticals. However,
implementation of this pharmacogenetic knowledgeto the clinic has proven to be challenging and to
require collaboration between the various
stakeholders throughout the discovery, development
and validation stages so as to ensure the utility of
actionable genetic testing in a cost-effective manner.
The challenges of poly-pharmacy are of particular
importance to be considered by individualised
targeting. Targeted therapy and reliable prediction of
expected outcomes offer patients access to better
healthcare management, by way of identifying the
therapies effective for the relevant patient group,
avoiding prescription of unnecessary treatment and
reducing the likelihood of developing adverse drug
reactions [35].
17.Laboratory Medicine (responsible editors: Marko
Kapalla, Slovak Republic, and Elvar Theodorsson,
Sweden)
The section is focused on predictive and prognostic
laboratory tests considered as the robust platform
for more precise diagnosis, targeted prevention and
treatments tailored to the person. Current deficits in
medical services such as delayed intervention,
untargeted medication, overdosed patients and
ineffective treatments require the role of laboratory
shifted from the ‘passive performing’ to the ‘active
advising’ one. Recommendations by the laboratory
to assist clinical practice are highly desirable. This
assistance ranges from advising on the necessity for
additional tests to the dynamic analysis of the
targets. Additional tests should be considered from
the viewpoint of their reasonability, in order to
reach an accurate and realistic health-related data
interpretation for the individual. The analysis of
dynamic changes of the target is essential to evaluate
potential health impacts such as an individual
predisposition to the disease and/or a predictive
diagnosis before a clinical manifestation of symptoms.
Laboratory value-added investigation and interpretation
should be obligatory in creating an advanced functional
relationship between laboratory medicine and clinicians
together as the responsible decision-makers [36-38].
18.Biobanking and Biopreservation (responsible
editor: Judita Kinkorova, Czech Republic)
Internationally valid biobanking is currently an
ongoing process, facing major viability challenges
which are in the focus of this section. As for
individual types of biological material (tissue
samples, blood samples, DNA, RNA, proteins,
metabolites, etc.), unified/standardised instructions
and legal approaches should be validated how
samples may be collected, stored, retrieved, shared
and tested. The analytical quality of collections,
storage condition and donation of samples to a
biobank require a strict control both at national and
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require acquired samples to be retrospectively valid
for a development of novel biomarkers and novel
drugs/treatments. For a disease-specific biobanking,
patients should be stratified with immaculate
record-keeping, to enable to draw conclusions on
the new markers. The functional link to the reliable
clinical data and interpretation is crucial for the utility
of any biobank [36,39].
19.Biomarkers (responsible editors: Suzanne Hagan,
UK, and Byong Chul Yoo, South Korea)
If biomarkers are discovered, are they applicable to
diagnostics, treatment targets/monitoring or both? Is
a biomarker defined on a molecular basis? Does one
biomarker unambiguously define corresponding
pathology? Does a new diagnostic approach apply to
groups of risks and targeted prevention? Is a multi-level
biomarker panel applicable/available to secure a precise
diagnose and therapy targeting? This section is in a
mission to respond to the above questions [40-42].
20.Medical Chemistry (responsible editor: Jorge F. J.
Coelho, Portugal)
This section involves a multidisciplinary approach
that ranges from the application of innovative active
therapeutic medicines to advanced methods for
controlled delivery. Particular attention is paid to
outstanding developments involving structure—
biological activity relationships in different areas of
interest for this topic, such as: stem cells; rational
drug design, new (co)polymers; creation of tailor-made
drug delivery systems; incorporation of target
molecules to the polymeric structures; encapsulation
of approved drugs with the polymers; preparation and
characterisation of nanoparticles for in vivo
diagnostics and treatment; and evaluation and
validation of new systems in vitro and in vivo
studies [43-46].
21.Design (responsible editors: Antony Kent, UK, and
Guglielmo M. Trovato, Italy)
The specific challenge for multidisciplinary
communication is the design of media to facilitate
effective interaction amongst professional groups in
PPPM. These groups currently ‘speak different
languages’ which reinforce each group’s professional
perspective and frequently underestimates the added
value of the transfer of products between disciplines.
The specific output of this designing activity is the
so-called ‘professional interactome’ and the
representation of complex networks of information.
The interactome represents the most optimal model
of healthcare organisation designed specifically for the
implementation of an effective interaction amongst
professional groups in PPPM that creates the main
focus of this section. Recognising the need forengagement and to enhance an patient’s ease of access
to, and usability of, services and products, the design
principles of envisioning and empathy, ergonomics
and prototyping will be applied to the conceptualisation
and development of personalised services (service and
experience design) and personal medical devices
(product design). Since ‘style in the life’ is one of
the most important factors affecting health status
and its perception, particularly in youngsters, design in
the wider sense of the concept and, namely, fashion’s
trends strongly influences media, health-related
behaviours, body size, shape and appearance
perception. For these reasons, multidimensional
assessment and intervention aimed to favourable
modifications of lifestyles should include the awareness
that urban, home and work design, even clothing and
fashion and related industries, can be addressed to the
enhancement of PPPM intervention [47].
22.Education (responsible editor: Ondrej Topolcan,
Czech Republic)
This section aims at creating new didactic and
educational measures, including e-learning tools,
conducting important information for all PPPM
relevant professional groups (medical doctors, students,
nurses, etc.), patients and their family members as well
as individuals as risk and targeted groups in
populations, introducing innovative concepts of
PPPM and shifting the paradigm from delayed
reactive care, to predictive and preventive medical
care. It will distinctively draw on current multimedia
design practices (see the above paragraph 21) to create
attractive and motivational learning materials as well
as communications targeted to key groups. The
ultimate goal of this activity is to support the creation
of a new generation of professionals in medicine who
will be able to implement a holistic approach to
patient care that recognises the complexity and
individuality of any organism instead of treating the
patient as a disaggregated ‘pool of organs’ [48,49].
23.Business Models (responsible editor: Frank
Heemskerk, Belgium)
Poor economy of healthcare systems and delivery is
in the focus of this section. Across Europe, there is a
great diversity of systems, payment and
reimbursement schemes. This imposes a highly
fragmented market (market access is governed by
various public and private organisations) which
raises the efforts (seeking recognition, market
authorisation and reimbursement in 28 different
countries and respective bodies) and the costs (all
different bureaucratic schemes) considerably. On the
one hand, there is a need for policy dialogue to
achieve some harmonisation in rules and delivery
but also in access and reimbursement for patients
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great need for more advanced business models
(what is the offer?, who benefits?, who pays?) to
motivate all stakeholders for better scientific
achievements, more effective implementation,
improved medical services and interest in the
general population to follow the strategies of
predictive and preventive medicine for cost-effective
healthcare. In the light of economic strain and with
ageing populations, this innovation in the healthcare
systems is critical to keep the high quality of healthcare
we have in Europe affordable and sustainable [50,51].
24.PPPM Centres—the nucleus for advanced
healthcare (EPMA working group: Vincenzo
Costigliola, Belgium; Josef Flammer, Switzerland;
Mikhail Paltsev, Russia; Marko Kapalla, Slovak
Republic; Juraj Kuban, Slovak Republic; Kurt
Krapfenbauer, Austria; Olga Golubnitschaja,
Germany)
Successful PPPM implementation requires an
unprecedented level of collaboration amongst all
stakeholders, long-term multidisciplinary
professional partnerships including public-private
ones, robust juristic platform and smart political
regulations. It is important that future developments
are focused on the integration of all elements of
PPPM. Innovative PPPM centres are focused on
designing and conducting a new culture in healthcare:
high level of multidisciplinarity, innovation and
professional education, well-met patient needs,
cost-effective economy of healthcare, etc.
Collaboration with other professional groups
leading dedicated medical fields relevant for
PPPM
Below listed professional networks have clearly nomi-
nated areas of professional interests tightly linked to the
EPMA objectives. Corresponding agreements have been
signed creating a robust platform for successful bilateral
collaborations in a long-term way.
European Medical Association (EMA, www.emanet.
org); EPMA and EMA support each other developing
complementary activities in disseminating PPPM rele-
vant information, providing high-quality professional
education, performing daily work with patient organisa-
tions and implementing innovative approaches to advance
medical services in Europe.
European Society of Radiology (ESR, www.myesr.
org); EPMA and ESR have proclaimed the long-term
partnership and mutual support in effective promotion
of common efforts in the predictive diagnostics, targeted
preventive measures and personalised patient treatment
in the European healthcare and in global scale. The de-
velopment of professional synergies between EPMA andESR are expected to lead to much progress in the PPPM
generally and, in particular, strengthen the role of the
issue-related European networks. Considering these
clear strategic benefits, both EPMA and ESR decided to
collaborate considering following items:
– creation of expert recommendations for advanced
healthcare
– collaborative promotion of innovative medical fields
and the philosophy of integrative medicine
– collaborative development of scientific projects
dedicated to translational medicine and practical
application of innovative technologies in routine
medical practice
– networking of institutional members in Europe and
worldwide
– mutual enrichment of the long-term strategies and
outlook in PPPM by concepts development and
regular publishing of position articles in both
journals—The EPMA Journal and European Radiology
– mutual support of educational and training
programmes by inviting experts and providing
expertise related to diverse branches of PPPM
– creation of innovative didactic materials for
PPPM-related educational and training programmes
– collaborative development of granting strategies and
synergies in setup of innovative projects related to
PPPM, e.g. in the European ‘Horizon 2020’
– creation of specialised EPMA/ESR workshops at the
regular EPMA World Congresses and ESR
Congresses
– Mutual support in publicity (website, public relation,
etc.).
European Federation of Clinical Chemistry and
Laboratory Medicine (EFLM, www.efcclm.org); EFLM
provides European leadership in clinical chemistry and
laboratory medicine. Both EPMA and EFLM consider
the integrative approach by PPPM as the medicine of
the future. In furtherance of their mutual interest in ad-
vancing the healthcare paradigm from reactive to pre-
dictive, preventive and personalised medicine and in
laboratory medicine as the integrating element in PPPM,
the two organisations recognise the added value of work-
ing together and initiate the establishment of the joint
Working Group (WG). The strategic document about
EPMA/EFLM professional synergies recently has been
published in The EPMA Journal to define clear priorities
of the collaboration [36].
European Society of Predictive Medicine (EUSPM,
www.euspm.org); EPMA and EUSPM are joining the
efforts for the predictive diagnostics, targeted preventive
measures and personalised patient treatment in the Euro-
pean healthcare. Professional synergies are developed,
Golubnitschaja et al. The EPMA Journal  (2015) 6:4 Page 10 of 11and bilateral support is provided concerning all scientific,
granting, publication, practical application and any other
network-related activities.
European Depression Association (EDA, www.eur-
opeandepressionday.com); EDA is interested in profes-
sional collaboration with the EPMA focusing specifically
on predictive diagnostics, targeted prevention and ad-
vanced person-centred approaches for the most optimal
treatment of depression as the stratified patient cohort.
European, Middle-Eastern and African Society for
Biopreservation and Biobanking (ESBB, www.esbb.
org); Designed as being reliable for advanced healthcare
services, biobanking considers the interests of all parties
involved in the research and business. International bio-
banking is in a focus of both EPMA and ESBB creating
the solutions to the below listed unmet needs, namely
 How can local and international barriers be broken
down to unify international biopreservation
technologies, sample collections and databases?
 Who carries the role to promote in the process of
biobanking internationalisation?
 Who should cover the costs of the internationally
accessible systems?
 Who is allowed to legally use these international
biobanks once they are created?
 Who could be nominated as the end user of the
data collected?
EPMA is open for collaboration with other leading
European and global professional networks relevant for
the effective promotion of PPPM.
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